VIR Stock Overview
An immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vir Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.76 |
| 52 Week High | US$13.09 |
| 52 Week Low | US$7.52 |
| Beta | 0.46 |
| 11 Month Change | -10.91% |
| 3 Month Change | -30.78% |
| 1 Year Change | -29.45% |
| 33 Year Change | -84.99% |
| 5 Year Change | n/a |
| Change since IPO | -44.65% |
Recent News & Updates
Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results
Aug 03
Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
Jul 17Recent updates
Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results
Aug 03Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
Jul 17Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates
May 05Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 03Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Feb 28Sticking With Vir Biotechnology
Jan 17Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%
Aug 07Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive
Jul 24Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically
Feb 28Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 07Vir Biotechnology: Focus On Hepatitis B Development Could End Up Paying Off
Oct 12Vir Biotech gains 12% as U.S. govt. inks multi-year deal worth up to $1B
Oct 04Vir begins dosing in mid-stage study of VIR-2218, VIR-3434 for hepatitis D virus
Sep 22Shareholder Returns
| VIR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.1% | -4.0% | -4.4% |
| 1Y | -29.5% | 12.4% | 19.1% |
Return vs Industry: VIR underperformed the US Biotechs industry which returned 12.4% over the past year.
Return vs Market: VIR underperformed the US Market which returned 19.1% over the past year.
Price Volatility
| VIR volatility | |
|---|---|
| VIR Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VIR's share price has been volatile over the past 3 months.
Volatility Over Time: VIR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 587 | Marianne De Backer | www.vir.bio |
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Vir Biotechnology, Inc. Fundamentals Summary
| VIR fundamental statistics | |
|---|---|
| Market cap | US$1.06b |
| Earnings (TTM) | -US$483.04m |
| Revenue (TTM) | US$78.88m |
13.4x
P/S Ratio-2.2x
P/E RatioIs VIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIR income statement (TTM) | |
|---|---|
| Revenue | US$78.88m |
| Cost of Revenue | US$448.59m |
| Gross Profit | -US$369.71m |
| Other Expenses | US$113.33m |
| Earnings | -US$483.04m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.54 |
| Gross Margin | -468.72% |
| Net Profit Margin | -612.40% |
| Debt/Equity Ratio | 0% |
How did VIR perform over the long term?
See historical performance and comparison